Loading...
Hair loss has been described in postmarketing reports as a possible adverse effect of glucagon-like peptide-1 (GLP-1) receptor agonists (). In this observational study, investigators evaluated this association by analyzing data from a large health system, comparing adults with type 2 diabetes who started GLP-1 agonists with those who started sodium–glucose cotransporter-2 (SGLT-2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors. Incident alopecia was documented by diagnosis codes.
During mean follow-up of 2 to 3 years, the incidence of alopecia was slightly, but statistically significantly, higher with GLP-1 agonists than with SGLT-2 inhibitors or DPP-4 inhibitors (≈1.8% vs. ≈1.2%).
Most of the effects appear…